Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non Hodgkin's Lymphoma Refractory/Relapsed”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05544968
What this trial is testing

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Who this might be right for
Hodgkin DiseaseCD30-Positive Diffuse Large B-Cell LymphomaCD30+ Anaplastic Large Cell Lymphoma+4 more
Medical College of Wisconsin 42
Testing effectiveness (Phase 2)Study completedNCT01203020
What this trial is testing

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

Who this might be right for
Hodgkin's LymphomaNon-Hodgkin's Lymphoma
West Virginia University 22
Early research (Phase 1)Looking for participantsNCT07239323
What this trial is testing

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

Who this might be right for
B-Acute Lymphoblastic LeukemiaB Cell Non-Hodgkin's LymphomaMultiple Myeloma
Chongqing Precision Biotech Co., Ltd 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05451810
What this trial is testing

Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaClassic Follicular Lymphoma
Genmab 184
Not applicableNot Yet RecruitingNCT07614035
What this trial is testing

Identification of the Best Treatment Pathway for Patients With Relapsed/Refractory Lymphocytic B-derived Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin Lymphoma
IRCCS Azienda Ospedaliero-Universitaria di Bologna 70
Large-scale testing (Phase 3)Ended earlyNCT00006708
What this trial is testing

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
SWOG Cancer Research Network 7
Testing effectiveness (Phase 2)Study completedNCT00073957
What this trial is testing

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Beth Israel Deaconess Medical Center 25
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Study completedNCT04030195
What this trial is testing

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Who this might be right for
Non-Hodgkin's Lymphoma, RelapsedChronic Lymphoid Leukemia in RelapseNon-Hodgkin's Lymphoma Refractory+6 more
Precision BioSciences, Inc. 18
Early research (Phase 1)Study completedNCT04696432
What this trial is testing

C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's B-cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital 7
Not applicableStudy completedNCT00521430
What this trial is testing

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+3 more
Asan Medical Center 30
Early research (Phase 1)Looking for participantsNCT05272384
What this trial is testing

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin Lymphoma+3 more
National Cancer Institute (NCI) 32
Large-scale testing (Phase 3)Looking for participantsNCT07188558
What this trial is testing

Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Who this might be right for
Large B-cell LymphomaLymphoma, B-CellRelapsed Non-Hodgkin Lymphoma+6 more
Lyell Immunopharma, Inc. 400
Testing effectiveness (Phase 2)Study completedNCT03744676
What this trial is testing

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Who this might be right for
Lymphoma, Non-HodgkinLymphomaLymphoma, B-Cell+7 more
Juno Therapeutics, a Subsidiary of Celgene 104
Large-scale testing (Phase 3)Ended earlyNCT00562965
What this trial is testing

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma, Follicular
Pfizer 29
Very early researchUnknownNCT05105867
What this trial is testing

CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-hodgkin Lymphoma
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT04665765
What this trial is testing

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma UnclassifiableRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma+4 more
City of Hope Medical Center
Early research (Phase 1)UnknownNCT05410041
What this trial is testing

Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies

Who this might be right for
Acute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Beijing Boren Hospital 15
Early research (Phase 1)Study completedNCT00354926
What this trial is testing

Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma
Applied Molecular Evolution 67
Testing effectiveness (Phase 2)Study completedNCT00085696
What this trial is testing

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Who this might be right for
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Millennium Pharmaceuticals, Inc. 66
Next Page
41